TrialGlobe

Clinical trial

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Invitation only · Early Phase 1 · 1 countries · Registry ID NCT07092605

Invitation onlyEarly Phase 1Interventional

What this study is about

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionLongevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness

Full registry criteria

Inclusion Criteria: * New or existing AgelessRx patient * Adults (aged 18-65) * Any sex * Any ethnicity * BMI ≥ 20 kg/m\^2 * Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement. Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bariatric surgery * Use of other weight-loss medications currently or within the past 6 months * Contraindications to semaglutide * Significant psychiatric illness that may affect participation * Pregnant or breastfeeding individuals

Treatments and study arms

GLP-1

Drug

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

Placebo

Drug

Sublingual Placebo (weekly) for up to 6 months

Primary outcomes

Change in self-reported pain levels in participants microdosing GLP1s6 months

Participants will complete an extensive medical questionnaire every 4 weeks over a 24-week period to monitor self-reported pain levels

Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s6 months

CBC panel will be analyzed every 12 weeks over a 24-week period, reported in thousands of cells per microliter with the change from baseline reported as percent deviation and compared to normalized range of healthy individuals

Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s6 months

BMP panel will be analyzed every 12 weeks over a 24-week period, reported in mg/dL with the change from baseline reported as percent deviation and compared to a normalized range of healthy individuals

Change in mood in participants microdosing GLP1s6 months

Mood will be assessed every 4 weeks over a 24-week period using the SF-36 standardized questionnaire with deviation reported as percent change from baseline

Change in heart rate variability in participants microdosing GLP1s6 months

Participants will wear health devices with data monitored every 4 weeks over a 24-week period to observe change in heart rate variability, being defined as the variability of a participant's resting heart rate. Variability will be measured as an average deviation from baseline heart rate at each timepoint and reported as percent difference.

Changes in sleep patterns in participants microdosing GLP1s6 months

Wearable health device data will be monitored over the 24-week period assessing REM vs non-REM sleep and reported as a ratio

Change in frequency of physical activity in participants microdosing GLP1s6 months

The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in steps taken.

Change in frequency of physical activity in participants microdosing GLP1s6 months

The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in calories burned.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

AgelessRx🇺🇸 Ann Arbor, Michigan, United States
Open map